LI Bang qing , LU Pineng , HU Dayi
  • Department of Ca rdiology; People s Hospital; Peking University; Beijing 100044; China;
Simvastatin; Coronary heart disease
Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables References Cited by

Objective　 To evaluate the effectiveness and safety of simvastatin 40 mg daily use in treatment of coronary heart disease.
Methods 　The study was designed as before-after study in the same patients. One hundred and sixty seven patients with coronary heart disease were prescribed simvastatin 40 mg daily for 3 and 6 months. Total cholestero (TC), low-density lipoproteins cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), triglycerldes (TG), ALT and creatine kinase (CK) in serum before therapy and at the end of 3 months and 6 months treatment were dectected. Continuous data were analyzed by standard difference of blocked randomization and described by mean±SD. Dunnet-t test was used for multiple comparison of trial and control groups. Statistical difference was set up at P＜0.05. Success rate was assessed by chi square test at the end of 3 and 6 months treatment.
Results 　Simvastatin 40 mg/d significantly decreased the level of TC (P＜0.000 5), LDL-C (P＜0.000 5), TG (P＜0.05), and could elevate HDL-C (P＜0.05). There were 39.5% of patients whose LDL-C reduced below 70 mg/dl. One patient whose CK raised 5.6 times of upper line of normal range and 4 patients whose ALT raised more than 2 times of upper line of normal range withdrew. The reliability of simvastatin 40 mg/d was relatively good.
Conclusions 　Simvastatin 40 mg/d could significantly improve the lipid profile, and is relatively reliable in treatment of coronary heart disease.

Citation： LI Bang qing,LU Pineng,HU Dayi. Effectiveness and Safety of Simvastatin 40 mg Daily Use in Treatment of Coronary Heart Disease. Chinese Journal of Evidence-Based Medicine, 2005, 05(6): 479-481. doi: Copy